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Background: Over 600 different pathogenic mutations have been identified in the BRCA1 gene. Nevertheless,
numerous missense mutations of unknown biological function still exist. Understanding of biological significance of
these mutations should help in genetic counselling to carriers and their families.
Patients and methods: A total of 104 patients with breast and/or ovarian cancer whose genetic counselling
answered the criteria of the American Society of Clinical Oncology (ASCO 2003), were prospectively screened for
mutations in all coding exons of the BRCA1 gene by automatic direct sequencing.
Results: During these mutational screening procedures one case presented three mutations classified in the Breast
Cancer Information Core Database as unknown variants. These were 655A/G found in exon 8 of BRCA1, 1575T/C
and 1767A/C found in exon 11 of the same gene. The identification of the three unknown variants in the proband
(16SIRIO) and in her mother and sister indicates that such alterations exist in cis.
Conclusions: Our results suggest that the charge and stechiometry variations determined by the changes in the
amino acids Y179C, F486L and N550H might produce an effect on the conformation of the protein and, consequently,
on its function.
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introduction
The 5%–10% of cases of breast/ovarian carcinoma are
associated with hereditary genetic mutations and a high
penetrance of the oncosuppressor BRCA1 [1]. Genetic
alterations in this gene lead to a higher predisposition to breast
and ovarian cancer and confer a significantly higher risk of
endometrial, pancreas, cervix and prostate gland cancers [2].
The BRCA1 gene consists of 22 exons encoding a nuclear 1863
amino acid phosphoprotein. BRCA1 protein contains several
functional domains, which interact directly or indirectly with
a variety of molecules, including tumour suppressors,
oncogenes, DNA damage repair proteins, cell cycle regulators,
transcriptional activators and repressors [3, 4].
Over 600 different pathogenic mutations identified in the
gene BRCA1 have been reported in the Breast Cancer
Information Core Database (BIC) [5]; most of these are
frameshift or nonsense mutations that give rise to the
formation of truncated proteins; others instead are missense
substitutions or intronic variants, including those involved in
splicing, which have been linked with pathogenesis.
Recently, many studies have focused on the interpretation of
the unknown biological significance of missense mutations in
the gene BRCA1, defined as unknown variant (UV), with
the aim of determining whether they had a pathogenic or a
neutral role [6, 7]. Moreover, these functional and biochemical
alterations within the different protein domains must be
acquired in order to understand their role in cancer
predisposition and aid in genetic counselling.
During genetic screening of BRCA1 in Sicilian patients
with breast/ovarian cancer (BC/OC), selected according to
hereditary breast/ovarian cancer syndromes (HBOC) criteria,
the patient 16SIRIO presented three UVs in the gene. We
therefore examined other members of her family to assess
whether the UVs were present in cis and if their segregation
was associated with other neoplasias diagnosed in these
subjects.
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patients and methods
A consecutive series of 650 patients resident in Sicily with breast/ovarian
cancer diagnosed between 1999 and 2004 were prospectively recruited at the
‘Regional Reference Centre for the Characterisation and Genetic Screening
of Hereditary Tumours’ at the University of Palermo. Written informed
consent to genetic counselling was obtained from all patients recruited. This
protocol was conducted by an oncologist, a geneticist and a psychologist and
included information regarding personal and family history in order to
evaluate risk factors and genealogical tree. The latter was updated every year
and investigated retrospectively for at least three generations in patients with
breast/ovarian cancer or other types of tumours related to
BRCA1 mutations.
After considering different family relationships, a total of 104 patients,
selected during genetic counselling according to the criteria of the American
Society of Clinical Oncology (ASCO) [8], were screened for mutations in
all coding exons of the BRCA1 gene by automatic direct sequencing. In cases
of positive testing, the patients were invited to follow preventative
programmes for the early diagnosis of BRCA1-associated tumours and to
communicate the results to their first-degree relatives so that they might also
undergo genetic counselling. Even when genetic testing proved negative,
the relatives of such patients were encouraged to take a regular part in the
early diagnosis programmes because of their familial cancer risk. If the
genetic testing was unclear, the patient was informed in order to decide
whether or not to proceed to other types of biomolecular investigation.
The genomic DNA was extracted from peripheral blood according to the
instructions contained in the QIAamp DNA mini Kit (Qiagen, Hilden,
Germany). A 9700 thermal cycler (Applied Biosystem, Foster City, CA) was
used to perform the polymerase chain reaction (PCR) of all the exons and,
after dividing exon 11, of the 12 fragments of the gene BRCA1. The
fragments of amplicons were analysed by agarose gel electrophoresis at
a concentration ranging from 1.5% to 2%. Direct sequencing of the PCR
products was performed with a 3100 Avant Analyzer automatic sequencer
(Applied Biosystems, Foster City, CA).
The DNA samples from the 16SIRIO family members were screened
for BRCA1 mutations in exons 8 and 11. Screening of the 50 DNA controls
with any familial cancer history, sequenced for the positions 655A/C,
1575T/C and 1767A/C, were performed in order to verify that the three
variants were present together only in the 16SIRIO family.
results
During mutational screening of the gene BRCA1 in a group
of 104 Sicilian patients with hereditary and familial ovarian
and/or breast cancer selected in the Regional Reference Centre
for the Characterisation and Genetic Screening of Hereditary
Tumours (University of Palermo, Italy), one case presented
three missense mutations classified in the BIC database as
unknown variants. These were 655A/G found in exon 8 of
BRCA1 and 1575T/C and 1767A/C found in exon 11 of the same
gene (Table 1). Furthermore, the same patient showed the
intronic variation IV7-34 C>T, which was reported several
times in the BIC both as a polymorphism and as an UV; in our
negative controls, this intronic variant was detected in 70% of
the cases (35/50), both in homozygotes and in heterozygotes.
The patient, indicated by an arrow in the geneological tree,
was a nulliparous, non-Askenazi woman aged 35, with a
ductal infiltrating carcinoma of the left breast (T1NoMx),
intermediate grade (G2), positive to the test for
oestroprogestinic receptors (40%) and for MIB-1 (10%) and
negative for Erb-B2 (Table 2).
During genetic counselling, the patient’s geneological tree
was reconstructed together with her individual and family
clinical history, retrospectively for three generations. The
patient was included in our study because she was diagnosed
with breast cancer at an early age (<40 years old) and also
because of the tumour history in the first generation. The
patient’s mother had previously been diagnosed with
a tumour of the uterus (spinocellular, cheratoblastic and
endocervical infiltrating carcinoma) at the age of 42. All
members of the family, including the proband’s father,
mother and sister, underwent analysis of exons 8 and 11 of
the gene BRCA1. Direct automatic sequencing of DNA
extracted from the lymphocytes showed exactly the same UVs:
Y179C, F486L and N550H in the mother and the sister
(Figure 1). Furthermore, the patient’s father presented the
same polymorphic intronic variant IV7-34 C>T as the proband,
while the sister and the father showed S694S polymorphism
(Table 1). The identification of the three UVs both in the
mother and in the sister of the proband indicates that such
alterations exist in cis. None of the control cases presented
any of the three UVs.
discussion
The BRCA1 germinal mutations are responsible for the majority
of hereditary breast and/or ovarian cancers and they have also
recently been associated with a high risk for several other types
of tumours, such as those involving the prostate gland, the
pancreas and the endometrium [9, 10].
Since carriers of these mutations have a high risk of
developing these tumours at an early age, the American Society
of Clinical Oncology recommended genetic testing to be
performed to patients before the age of 40 years [11].
The patient 16SIRIO developed breast carcinoma at an early
age and analysis of her genealogical tree indicated that her
mother had been affected by endometrial carcinoma at a similar
age. This suggested that the patient was probably a carrier of
Table 1. Details of the five sequence variants of BRCA1 gene detected in the 16SIRIO family
Sequence variants Exon/intron Nucleotide no. Base change No. times in BIC Amino acid change Effect
Missense mutation Exon 8 655 A>G 35 Y179C UVs probably related to BC
when present simultaneouslyMissense mutation Exon 11 1575 T>C 36 F486L
Missense mutation Exon 11 1767 A>C 34 N550H
Intronic variant Intron 7 IVS7-34 C>T 7 – Neutral
Silent mutation Exon 11 2201 C>T 12 S694S Neutral
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a BRCA1 mutation. Genetic tests on the patient 16SIRIO
showed the presence of three UVs: 655A/G, 1575T/C and
1767A/C, which were also found in the patient’s mother and
younger sister, whereas none of these UVs were found in any of
the control cases. Furthermore, both the proband and her father
presented the intronic variation IVS7-34C/T, frequently
reported in the BIC both as a polymorphism and also as an UV.
This variant was found in 70% (35/50) of our control cases, both
in homozygotes and in heterozygotes, indicating therefore that
it was a benign nucleotide alteration. Moreover, both the
patient’s sister and father showed the nucleotide variation
2201C/T, which does not involve any amino acid variation
(S694S).
The analysis of the control cases with the same ethnic
background was important for determining whether the changes
detected in the BRCA1 genomic sequence are variants associated
with disease or benign variants that are typically found in the
Sicilian population.
It is known that the conformation and therefore the final
structure of a protein is the result of its amino acid composition
and consequently of the physico-chemical properties and
stechiometry of the amino acids. The three UV identified in this
report are mentioned several times in the BIC and determine
important amino acid changes: in fact, 655A/G gives rise to the
Table 2. Proband’s clinical features
Age at initial diagnosis 35
Family history of breast cancer Negative
Family history of ovarian cancer Negative
Laterality of breast cancer Left
Histology of breast cancer Ductal infiltrating
Tumour stage T1
Number of nodes involved 0
Histological grade 2
Oestrogen receptor status Positive
Progesterone receptor status Positive
Erb-B2 Negative
MIB-1 Positive (10%)
Figure 1. (A) Geneological tree with 16SIRIO proband indicated by arrow. Black circles indicate women affected by cancer. White square indicates
man without any mutation. Br, breast cancer; Ut, uterine cancer. Numbers following abbreviations indicate age at diagnosis. (B) Electropherogram
of exon 11 sequence (1767A/C) of BRCA1 gene in the proband.
Figure 2. Schematic diagram of BRCA1 polypeptide showing main functional domains (in grey). In the circles are indicated some of the proteins
interacting with BRCA1, whose interaction domains include the amino acids Y179, F486 and H550.
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substitution of thyrosine 179 characterised by the presence of an
aromatic ring, by cisteine, which possesses oxydrilic lateral
chains (Y179C, n. 35 times in the BIC); 1575T/C brings about
the substitution of phenylalanine 486, which also possesses an
aromatic ring, by leucine, which has aliphatic lateral chains
(F486L, n. 36 times in the BIC); and 1767A/C leads to the
substitution of the amino acid not charge asparagin 550 by the
amino acid basic histidine (N550H, n. 34 times in the BIC).
Several studies have been conducted to understand the
pathogenicity of BRCA1 unknown variants. The studies were
based on the alignment of the orthologous sequences and on
in vitro embryonal engineering (Xenophus and Mouse), where
UVs have been inserted in trans compared with deleterious
mutations of the same gene. These analyses demonstrated that if
Y179C, F486L and N550H are considered separately, they can be
classified either as neutral alterations or as changes with only
low clinical significance [12–14].
Combining these results and considerations with the study
of the 16SIRIO family, we suggest that three amino acid
changes identified might alter the charge and stechiometry of
protein, and in consequence its function. The latter might be
related to the change in BRCA1 interactions with proteins
whose binding domains include the amino acids Y179, F486 and
N550, for instance, TP53, SW1/SNF, ZBRK1/GADD45,
importin alpha, STAT1, ER and cMYC. These factors are
involved in DNA damage repair, cell cycle regulation and
transcriptional regulation [3, 4]. In particular, cMyc
oncogene interacts with two BRCA1 domains that include
Y179 and F486 (Figure 2).
An accurate follow-up of this family, and particularly of the
proband’s sister, might confirm the hypothesis that the three
amino acid alterations could play a role in determining breast
and/or ovarian cancer susceptibility. It might also be interesting
to study the segregation of the three variants in the carriers
affected by disease compared with those detected in the healthy
members of the family.
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